Mandate

Vinge has advised Egetis Therapeutics in connection with directed share issuances

October 03, 2024

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.

The share issuances were directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is subject to approval by an extraordinary general meeting as well as approval and publication of a prospectus.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge has advised Fidelio Capital AB in connection with its investment in Newsec AB

Vinge has advised Fidelio Capital AB in connection with the company’s investment in Newsec AB, a leading property asset management and advisory company in the Nordic and Baltic regions. Fidelio Capital AB has a vision to expand the business through, among other things, acquisitions and digital development within property management.
June 09, 2025

Vinge has advised Brand Equity Group Sweden AB in connection with its acquisition of PREVOX REKLAM Aktiebolag and Jonas Anderzson of Sweden AB

Vinge has advised Brand Equity Group Sweden AB in connection with its parallel acquisitions of PREVOX REKLAM Aktiebolag and Jonas Anderzson of Sweden AB. The acquired businesses are engaged in product media activities, with a primary focus on marketing and production of product media. Through these acquisitions, Brand Equity Group Sweden AB strengthens its position in Sweden within product media and brand communication.
June 09, 2025

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025